REFERENCES
- Porter JB, Shan FT. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies. Hematol/Oncol Clin North Am. 2010;24(6):1109–1130.
- Kolnagou A, Kontoghiorges GJ. New golden era of chelation therapy in thalassaemia: the achievement and maintenance of normal range body iron. Br J Haematol. 2010;150(4):489–490.
- Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol. 2007;138(4):407–21.
- Farmaki K, Tzoumari I, Pappa C, . Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol. 2010;148(3):466–475.
- Galanello R, Kattamis A, Piga A, . A prospective randomised controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia. Haematologica. 2006;91(9):1241–1243.
- Maggio A, Vitrano A, Capra M, . Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomised clinical trial. Br J Haematol. 2009;145(2):245–254.
- Wood JC, Noetzli L. Cardiovascular MRI in thalassemia major. Ann NY Acad Sci. 2010;1202:173–179.
- Meloni A, Positano V, Pepe A, . Preferential patterns of myocardial iron overload by multislice multiecho T*2 CMR in thalassemia major patients. Magn Reson Med. 2010;64(1):211–219.
- Pepe A, Meloni A, Capra M, . Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica. 2011;96(1):41–47.
- Hedeker D, Gibbons RD. Longitudinal Data Analysis. Hoboken: Wiley-Interscience. 2006.
- Galanello R, Campus S. Deferiprone chelation therapy for thalassemia major. Acta Haematol. 2009;122(2–3):155–164.
- Pontikoglou C, Papadaki HA. Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. Hemoglobin. 2010; 34(3):291–304.